诊断学理论与实践

诊断学理论与实践 >

2022 , Vol. 21 >Issue 01: 32 - 37

DOI: https://doi.org/10.16150/j.1671-2870.2022.01.007

指南解读

新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读

展开
  • 上海交通大学医学院附属瑞金医院呼吸与危重症医学科,上海交通大学医学院呼吸病研究所,上海市呼吸传染病应急防控与诊治重点实验室,上海 200025

网络出版日期: 2022-02-25

收起

本文引用格式

孙娴雯, 李庆云 . 新型冠状病毒疫情时期的慢性阻塞性肺疾病管理策略——2022版慢性阻塞性肺疾病全球倡议解读[J]. 诊断学理论与实践, 2022 , 21(01) : 32 -37 . DOI: 10.16150/j.1671-2870.2022.01.007

参考文献

[1] Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease[R/OL]. [2021-12-28]. https://goldcopd.org/2022-gold-reports/.
[2] 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J]. 中华临床感染病杂志, 2021, 14(2):81-88.
[2] State Health Commission of the people′s Republic of China. Diagnosis and treatment plan for novel coronavirus pneumonia (trial version of the eighth Revision)[J]. Chin J Clinic Infect Dis, 2021, 14(2):81-88.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组, 中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 新型冠状病毒肺炎疫情期间慢性阻塞性肺疾病医疗和防范须知[J]. 中华结核和呼吸杂志, 2020, 43(5):421-426.
[3] Chronic obstructive pulmonary disease group of respiratory branch of Chinese Medical Association, working committee of chronic obstructive pulmonary disease of respiratory branch of Chinese Medical Association. Notes on medical treatment and prevention of chronic obstructive pulmonary disease during the outbreak of novel coronavirus pneumonia[J]. Chin J Tubercul Respir, 2020, 43(5):421-426.
[4] Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor[J]. Cell. 2020 Apr 16; 181(2):271-280.
[5] Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study[J]. BMJ, 2020, 369:m1985.
[6] Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial[J]. Eur Respir J, 2021, 58(1):2100130.
[7] Streeck H, Schulte B, Kümmerer BM, et al. Infection fatality rate of SARS-CoV2 in a super-spreading event in Germany[J]. Nat Commun, 2020, 11(1):5829.
[8] de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study[J]. Lancet Infect Dis, 2020, 20(9):1034-1042.
[9] Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe COVID-19: a population cohort study[J]. Lancet Respir Med, 2021, 9(8):909-923.
[10] Reyes FM, Hache-Marliere M, Karamanis D, et al. Assessment of the Association of COPD and Asthma with In-Hospital Mortality in Patients with COVID-19. A Systematic Review, Meta-Analysis, and Meta-Regression Analysis[J]. J Clin Med, 2021, 10(10):2087.
[11] Press VG, Gershon AS, Sciurba FC, et al. Concerns About Coronavirus Disease-Related Collateral Damage for Patients With COPD[J]. Chest, 2020, 158(3):866-868.
[12] Munblit D, Bobkova P, Spiridonova E, et al. Incidence and risk factors for persistent symptoms in adults pre-viously hospitalized for COVID-19[J]. Clin Exp Allergy, 2021, 51(9):1107-1120.
[13] Kyung SY, Kim Y, Hwang H, et al. Risks of N95 Face Mask Use in Subjects With COPD[J]. Respir Care, 2020, 65(5):658-664.
[14] Samannan R, Holt G, Calderon-Candelario R, et al. Effect of Face Masks on Gas Exchange in Healthy Persons and Patients with Chronic Obstructive Pulmonary Disease[J]. Ann Am Thorac Soc, 2021, 18(3):541-544.
[15] Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial[J]. Lancet, 2022, 399(10321):237-248.
[16] 国家卫生健康委员会疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[J]. 中国病毒病杂志, 2021, 11(3):161-162.
[16] Bureau of disease prevention and control,National Health Commission. Technical guidelines for vaccination against novel coronavirus (First Edition)[J]. Chin J Viral Dis, 2021, 11(3):161-162.
[17] 中国医师协会呼吸医师分会肺功能与临床呼吸生理工作委员会, 中华医学会呼吸病学分会呼吸治疗学组肺功能专业组. 新型冠状病毒肺炎疫情防控期间开展肺功能检查的专家共识[J]. 中华结核和呼吸杂志, 2020, 43(4):302-307.
[17] Pulmonary function and clinical respiratory physiology Working Committee of respiratory physician branch of Chinese Medical Association, Respiratory therapy group and pulmonary function professional group of respiratory disease branch of Chinese Medical Association. Expert consensus on lung function examination during the prevention and control of novel coronavirus pneumonia[J]. Chin J Tubercul Respir, 2020, 43(4):302-307.
[18] Bhatt SP, Bodduluri S, Raghav V, et al. The Peak Index: Spirometry Metric for Airflow Obstruction Severity and Heterogeneity[J]. Ann Am Thorac Soc, 2019, 16(8):982-989.
[19] Ji C, Xia Y, Dai H, et al. Reference values and related factors for peak expiratory flow in middle-aged and elderly Chinese[J]. Front Public Health, 2021, 9:706524.
[20] Cen J, Ma H, Chen Z, et al. Monitoring peak expiratory flow could predict COPD exacerbations: A prospective observational study[J]. Respir Med, 2019, 148:43-48.
[21] Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective[J]. Chronic Obstr Pulm Dis, 2020, 7(2):73-75.
[22] Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China[J]. N Engl J Med, 2020, 382(18):1708-1720.
[23] Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysio-logy, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019(COVID-19): A Review[J]. JAMA, 2020, 324(8):782-793.
[24] Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(30):993-998.
[25] Carfì A, Bernabei R, Landi F, et al. Persistent symptoms in patients after acute COVID-19[J]. JAMA, 2020, 324(6):603-605.
[26] van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1[J]. N Engl J Med, 2020, 382(16):1564-1567.
[27] Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme in patients with COPD: a multicentre randomised controlled trial[J]. Thorax, 2017, 72(5):415-423.
[28] 新型冠状病毒肺炎恢复期中西医结合康复指南(第一版)[J]. 天津中医药, 2020, 37(5):484-489.
[28] Guidelines for the rehabilitation of novel coronavirus pneumonia in the convalescent period by combining traditional Chinese and Western Medicine (First Edition)[J]. Tianjin Tradit Chin Med, 2020, 37(5):484-489.
[29] Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations[J]. Nat Commun, 2018, 9(1):2229.
[30] Finney LJ, Glanville N, Farne H, et al. Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon[J]. J Allergy Clin Immunol, 2021, 147(2):510-519.
[31] Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells[J]. Respir Investig, 2020, 58(3):155-168.
[32] Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective[J]. Eur Respir J, 2020, 55(5):2001009.
[33] Schultze A, Walker AJ, MacKenna B, et al. Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform[J]. Lancet Respir Med, 2020, 8(11):1106-1120.
[34] Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic[J]. J Am Coll Cardiol, 2020, 75(18):2352-2371.
[35] Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms[J]. JAMA, 2021, 325(1):59-68.
[36] Zhao Q, Meng M, Kumar R, et al. The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis[J]. J Med Virol, 2020, 92(10):1915-1921.
[37] Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence[J]. Tob Induc Dis, 2020, 18:20.
Options
文章导航

/

〈 〉